Case Report: Remediating Cognitive Impairments in Dementia of Alzheimer’s Type Through Concurrent Transcranial Direct Current Stimulation and Cognitive Training: A Case Report

Sanaz Tajadini1, Neda Mohammadi1,2, Mahshid Tahamtan1,2,3*, Mohammad Nami1,2,3

1. Department of Neuroscience, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.
2. DANA Brain Health Institute, Shiraz, Iran.
3. Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

* Corresponding Author:

Mahshid Tahamtan, PhD

Address: Department of Neuroscience, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.

Tel: +98 (71) 32305471

E-mail: mahshidtahamtan@yahoo.com

Objectives: Dementia of Alzheimer Type (DAT) is associated with progressive cognitive impairments. Such a clinically significant condition is known to affect approximately 9.5% of people over 70 years of age. However, it is accepted as a more challenging medical entity because of its increasing atypical presentation, rarity of efficient treatments, and diagnostic and prevention challenges.

Materials & Methods: we present a case who referred with 5 months history of cognitive decline following Medial Temporal Lobe (MTL) atrophy upon neuroimaging. Following cognitive and neurophysiological assessments, she underwent 21 consecutive sessions of transcranial Direct Current Stimulation (tDCS) 3 times per week. Concurrently, a media-rich computer platform was administered for cognitive and behavioral remediation.

Results: Based on the evidence regarding the use of tDCS in dementia, we aimed at stabilizing the cognitive profile and halting or slowing down the process of progressive cognitive decline in the present case. The outcome of our neuromodulatory intervention using tDCS supported the beneficial impact of such an approach in not only stabilizing but also ameliorating cognitive functions. This is especially important when rapid progression of cognitive symptoms in DAT is of concern.

Conclusion: The promising clinical course of this specific case supports the possible beneficial effects of tDCS in halting the progression of symptoms in DAT. Sham-controlled clinical trials would get momentum to highlight clinical impact of such an intervention in DAT.
1. Introduction

Dementia of Alzheimer Type (DAT) is a ubiquitous neurodegenerative process and the most common cause of dementia in the elderly, with substantial cost burden on individuals and the society [1]. It is associated with senility and affect approximately 9.5% of people older than 70 years [2]. Regarding its adverse effects on the quality of life, life expectancy, and societal costs, the World Alzheimer Report and World Health Organization recommend dementia care as a public health priority [3].

DAT is commonly associated with Mild Cognitive Impairment (MCI), which may contribute to the decline in daily functioning, learning, executive functions, and contribute to the minor linguistic problems, loss of memory and attention deficits [4]. MCI results from actual damage to lateral frontal and medial temporal regions. This damage can lead to defects in learning new information and retrieving old memories [5]; however, depression, anxiety and irritability may also manifest in DAT patients [6].

Therefore, lack of effective interventions have diverted the attention toward successful therapeutic strategies as a major goal in health interventions in order to improve or prevent DAT [7]. In this regard, as a new non-invasive and neuro-modulatory technique, transcranial Direct Current Stimulation (tDCS) has been widely used in DAT individuals to improve their cognitive capacities [8], and alter brain activity in specific regions with its weak direct current over the patients’ scalps [9].

Based on clinical practice of tDCS in patients with DAT, it can improve cognitive functions, due to its ability in altering excitability of brain cells [10-12]. However, a few studies have reported negative results [13, 14]. A reasonable interpretation would be due to montage used, different participants, or the method of evaluation. To this end, we present a woman suffering from DAT with cognitive decline. We present this case discussion to gain more insight over online neuro-modulatory (tDCS) effects on stabilizing the cognitive decline in patient with DAT.

2. Case Report

Patient’s information

The patient was a 55-year-old woman, housewife, and native Persian speaker with 5 years formal education. She presented to our Neuroscience Laboratory with a 5-month history of cognitive decline following Medial Temporal Lobe (MTL) atrophy. Based on her daughter’s report, she frequently repeated herself, distracted and failed to connect with others. However, her main complaints were recent weakening in working memory, attention, executive functions, and language reconstruction. She had dysarthria and poverty of speech.

Clinical findings and diagnostic assessment

According to patient’s Quantitative Electroencephalography (QEEG) rhythms based on frequency bands and functional cortical connectivity and neuropsychiatric assessments, the clinical diagnosis of DAT was confirmed. A 24-ch QEEG recording was administered, using the NR-sign amplifier through 10-20 system, in two phases. In phase one, data were recorded while the patient kept her eyes open in a relaxed state, without moving or talking. On examination, background activity was normal, but the patient exhibited lower power density in posterior alpha waves (8-12 Hz). Furthermore, FFT analysis showed increased widespread theta (4-7 Hz) rhythms in bi-temporal regions mainly on the left hemisphere.

On the second phase, during repetition verbal memory task, the results showed a coherent decrease in QEEG rhythms at F7-T5 electrodes in the beta band (13-30 Hz), and also lack of high beta power density in frontopolar brain regions. Finally higher power density of theta waves in left frontotemporal suggested verbal memory deficits (Figure 1).

The patient also underwent general cognitive assessment (Montreal Cognitive Assessment [MoCA]), as a measure of her general cognitive status; language, memory, attention, and executive function [15]. The results are presented in Table 1. Clinical symptoms, QEEG results, and below cutoff scores for normal performance on MoCA confirmed the proposed diagnosis for early-onset DAT.

Therapeutic intervention

Experimental protocol

After analyzing the patient’s baseline performance and taking her consent, we recommended 21 tDCS sessions, 3 times per week, in combination with Cognitive Behavioral Therapy (CBT) and other behavioral online interventions. In the following, the different procedural phases for offline and online tDCS are shown in their temporal order (Figure 2).

tDCS

Two-channel tDCS was bilaterally delivered by a battery-driven current stimulator connected to 4 sponge...
electrodes. We used the saline-soaked synthetic sponge for tDCS to minimize skin resistance. Two stimulation electrode (the anodes) sites were left temporal and prefrontal cortex, positioned over F3 and T3. Cathodal electrodes were placed over F4 and FP2 based on the 10-20 EEG international system. A constant current intensity of 2 mA was applied for 45 minutes for every session. During each session, there was a ramping period of 10 s.

Online tDCS experiments (cognitive assessments)
To monitor prodromes and modify patient’s behavior, we used four different tasks: Cognitive Behavioral Therapy (CBT), Rey Auditory Verbal Learning Test (RAVLT), Purdue pegboard test, and match-to-sample task. To screen the patient’s explicit memory and short-term auditory-verbal memory impairments, CBT and RAVLT.

Table 1. Score of the subject in some subtests of MoCA

<table>
<thead>
<tr>
<th>Tasks</th>
<th>Raw Score</th>
<th>Results</th>
<th>Cutoff</th>
</tr>
</thead>
<tbody>
<tr>
<td>Executive</td>
<td>0.5</td>
<td>Below</td>
<td>-</td>
</tr>
<tr>
<td>Naming</td>
<td>0.3</td>
<td>Below</td>
<td>-</td>
</tr>
<tr>
<td>Memory</td>
<td>2.5</td>
<td>Below</td>
<td>-</td>
</tr>
<tr>
<td>Attention</td>
<td>1.6</td>
<td>Below</td>
<td>-</td>
</tr>
<tr>
<td>Language</td>
<td>1.3</td>
<td>Below</td>
<td>-</td>
</tr>
<tr>
<td>Abstractor</td>
<td>0.2</td>
<td>Below</td>
<td>-</td>
</tr>
<tr>
<td>Orientation</td>
<td>2.6</td>
<td>Below</td>
<td>-</td>
</tr>
<tr>
<td>Total</td>
<td>6.30</td>
<td>-</td>
<td>Normal&gt;26</td>
</tr>
</tbody>
</table>

The patient had taken Exelon 3 mg QD, Memantine QD, and Alzixa QHS.
questionnaires were administered to obtain a stable online experimental phase, in which the patient was asked to recall more positive and neutral words and also repeat different word trials after hearing them.

The patient’s eye-hand coordination, gross muscle coordination of the arms and hands, and fine motor coordination of the fingers were assessed using uni- and bi-manual dexterity (pegboard). Visual matching ability was assessed with short-term visual recognition memory task (match-to-sample). In general, based on pegboard instruction, three separate sections were administered: right hand alone; left hand alone; and both hands. The mean number of pegs the patient placed in the board for 3 consecutive trials (bar, ring, and cylinder) served as the test score. The standard administration lasted 30 s per trial. The match-to-sample task comprised three successive levels which in each level the patient required to remember, identify, and push the shapes to match stimuli. Follow-up visit was recommended.

3. Results

Here, we report the results of different analysis to certify the clinical conditions of the present case report. The patient attended all experimental sessions. After completing the clinical trials, the patient in both CBT and RAVLT tests showed stable functioning during stimulation condition (7.10 and 15.15 points, respectively). Of note, these procedures were repeated for two sessions after the first week of offline tDCS. During the 5-session period, the pa-
tient’s sensorimotor functions on pegboard task improved in each section (Figure 3). For the other online cognitive experiment, the performance on match-to-sample task was analyzed; one-week patient’s attention and visual recognition memory was observed during S1, S2 at level 2 and S1, S2, and S3 at level 3. In accordance with our expectations, there was an increasing trend in patient’s performance during S3, S4 at level 2 and S4 at level 3 (Figure 4).

**Treatment and follow-up**

Following the neurostimulation and neuropsychological procedures, improvement of cognitive functions

**Table 2.** Non-invasive stimulation studies targeting cognitive and neuropsychiatric symptoms in dementia

<table>
<thead>
<tr>
<th>Study</th>
<th>Patient Group</th>
<th>Treatment</th>
<th>Stimulation Parameters</th>
<th>Outcome Measures</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boggio et al. (2009)</td>
<td>AD (n=10; NINCDS-ARDA criteria with MMSE of 12-25)</td>
<td>tDCS</td>
<td>Active (2 mA for 30 minutes) or sham (2 mA for 30 seconds) stimulation (35 cm² electrodes). Anode placed on left DLPFC (F3) or left temporal cortex (T7) with cathode on right supraorbital area. Left DLPFC, left temporal cortex and sham stimulation given in counterbalanced manner with 48 hours washout period between each condition.</td>
<td>Selective attention (stroop), working memory (backward and forward digit span) and visual recognition memory tasks</td>
<td>Improvement shown in visual recognition memory task after active stimulation (approx. 18% improvement after temporal and 14% after prefrontal stimulation) compared to sham.</td>
</tr>
<tr>
<td>Boggio et al. (2012)</td>
<td>AD patients (n=15; NINCDS-ADRDA and DSM-IV criteria, no other neuropsychiatric diseases and MMSE&gt;15)</td>
<td>tDCS</td>
<td>Active or sham anodal stimulation (2 mA for 30 min) delivered to T3 and T4 bilaterally (35 cm² electrodes with 64 cm² electrode placed over right deltoid muscle) for 5 consecutive days.</td>
<td>MMSE, ADAS-Cog, visual recognition and visual attention tasks</td>
<td>Improvement shown on visual recognition task compared to baseline after active stimulation, with improvements sustained at 1 month follow-up period (11.4% improvement). No effects shown on MMSE, ADAS-cog or visual attention.</td>
</tr>
</tbody>
</table>
persisted 3 months after tDCS application. To keep the patient’s cognitive functions, she was advised to stop her previous medications and switch to piracetam, donepezil, Ritalin, neurazol, and vitamin E. The follow-up evaluation in our laboratory suggested a notable subjective improvement in her social scale quality and her family members reported significant behavior changes like her reducing anxiety, aggression, and depression, and also improvement in speech fluency.

4. Discussion

Based on the previous studies, Alzheimer Disease (AD) is the most common cause of dementia. It also determines the loss of cognitive functioning with increasing age [16, 17]. The worsening clinical situation of the patient in addition to the degree of impairments in cognitive function forced us to perform stimulation technique. Suggesting the positive role of tDCS on cognitive deficits, there have been only a few case reports in which benefits were realized by consecutive sessions of tDCS applied over the temporal and frontal areas [18, 19]. This report therefore extends previous findings by showing significant improvement in learning and recognition memory via concurrent delivery of tDCS [20, 21]. Accordingly, from our experience with this patient, we tend to agree with the results from a comprehensive literature search on tDCS studies in AD subjects until March 2017 in which 12 articles with a total of 202 AD participants demonstrated positive results with tDCS regarding their improvement in cognition [22]. Moreover, Table 2 presents details regarding the information related to the tDCS effects in four studies [23-26]. Generally, despite the well-known positive effects of tDCS as an adjuvant treatment for patients with AD, the conclusion of this report is limited due to the results of a single case. However, it was important for us to share this unique patient as a case report who experienced multi-cognitive impairments under brain stimulation and various cognition assessment in different domains. However on the basis of clinical features, parameters such as duration and intensity of stimulation are as casual factors underlying tDCS effects [27]. We hope that by reporting this case, further studies involving newer techniques like high-definition tDCS and multimodal neuroimaging investigations were carried out that can have important implications for clinical situation regarding neural basis of tDCS effects in DAT.

<table>
<thead>
<tr>
<th>Study</th>
<th>Patient Group</th>
<th>Treatment</th>
<th>Stimulation Parameters</th>
<th>Outcome Measures</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cotelli et al. (2010)</td>
<td>AD patients (n=14)</td>
<td>tDCS</td>
<td>4-week active tDCS (unspecified treatment parameters) or 2-week sham tDCS followed by 2-week active stimulation.</td>
<td>MMSE, unspecified neuropsychological and action-object naming tasks</td>
<td>Incomplete pilot study: Improvements in MMSE, action naming and noun-naming tests at 12-week follow-up [changes in MMSE and tests not specified]</td>
</tr>
<tr>
<td>Ferrucci et al.  (2008)</td>
<td>Probable AD (n=10; NINCDS-ADRSA and DSM-IV criteria, with MMSE&gt;20).</td>
<td>tDCS</td>
<td>Stimulation (1.5 mA for 15 min; 0.06 mA/cm² current density) with one electrode placed over scalp and reference over right deltoid muscle. Anodal, cathodal or sham tDCS delivered bilaterally to tempoparietal areas (P3-T5 on left side and P6-T4 over right side) in a random order with a minimum 1-week interval between stimulation.</td>
<td>Word recognition and visual attention tasks</td>
<td>Word recognition improved after anodal tDCS (↑2.4 correct responses), remained the same after sham stimulation and worsened after cathodal stimulation (↓2.6 correct responses; at 30 minutes post-tDCS compared to baseline). No effects observed on visual attention task.</td>
</tr>
</tbody>
</table>
Ethical Considerations

Compliance with ethical guidelines

The informed consent was obtained from the subject declaring that his clinical data would be used in our institutional research database.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of interest

The authors declared no conflict of interest.

References


